

Antibody	Specificity	Breadth	VH	SHM	HCDR3 Length	Screening Strategy
2F5	gp41 MPER	6070%	25*	15.2	24	gp160 and p24 binding
4E10	gp41 MPER	9698%	169	15.6	20	gp160 and p24 binding
1EO8	gp41 MPER	98%	315	22.1	22	Microneutralization
2G12	gp120 glycans	2530%	321	33.6	16	gp160 and p24 binding
PGT128	Glycans and V3 -strand	7075%	439	27.9	21	Microneutralization
PGT127	Glycans and V3 -strand	50%	439	23.2	21	Microneutralization
PGT121	Complex type V3 N-glycans	6570%	459	21.2	26	Microneutralization
10-1074	Complex type V3 N-glycans	5560%	459	24.4	26	gp140 binding
PGT135	Glycans and V4	3035%	439	26.8	20	Microneutralization
PG9/PG16	Glycans and V1/V2	7580%	333	15.416.8	30	Microneutralization
CH01 CH04	Glycans and V1/V2	50%	320	23.319.5	26	Microneutralization
PGT145	Glycans and V1/V2	7580%	18	22.8	33	Microneutralization
b12	gp120 CD4bs	3035%	1-3	17.3	20	Phage library
HJ16	gp120 CD4bs	3035%	330	36.7	21	EBV- immortalization
VRC01	gp120 CD4bs	9095%	12	38.8	14	Cell sorting/RT-PCR
VRC03	gp120 CD4bs	50%	12	34.9	16	Cell sorting/RT-PCR
3BNC117	gp120 CD4bs	8590%	12	36.9	12	Cell sorting/RT-PCR
3BNC60	gp120 CD4bs	NA	12	36.9	12	Cell sorting/RT-PCR
NIH45-46	gp120 CD4bs	90%	12	44	18	Cell sorting/RT-PCR
CH30 CH34	gp120 CD4bs	80%	12	31.931.9	15	Cell sorting/RT-PCR
PGV04	gp120 CD4bs	8590%	12	38.2	16	Cell sorting/RT-PCR
3BC176	CD4i/V3	6070%	12	29.4	19	Cell sorting/RT-PCR

Table 1: Add caption